Deal Update: Taking Stock of Biogen Idec

Like the merger that created Biogen Idec, its new collaboration with PDL is an example of how biotechs can combine to help achieve critical mass. But Biogen Idec still has a lot of heavy lifting to do, especially in one key therapeutic area-oncology.

More from Business Strategy

More from In Vivo